You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
开拓药业(09939.HK)ALK-1抗体联合治疗法总体缓解率达40%
阿思达克 01-20 14:01
开拓药业(09939.HK)公布,其ALK-1抗体GT90001联合Nivolumab二线治疗晚期肝细胞癌(HCC)患者II期临床试验,积极资料已在2021年美国临床肿瘤学会胃肠道肿瘤研讨会上发布,结果显示联合疗法的疗效令人鼓舞且安全性良好。有效性方面,患者总体缓解率为40%,有8例患者出现部分缓解,目前已有2例患者治疗时间超过1年。

开拓药业董事长兼首席执行官童友之表示,将在中国和美国积极布局开展多个治疗晚期HCC的国际多中心的II/III期临床试验,同时对治疗其它实体瘤进行探索,使更多肿瘤患者受益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account